Lymphomas with kidney involvement: the French multicenter retrospective LyKID study

References

• Richmond J, Sherman RS, Diamond HD, et al. Renal lesions associated with malignant lymphomas. Am J Med. 1962;32(2):184–207.
   PubMed Web of Science ®Google Scholar
• Sandrasegaran K, Menias CO, Verma S, et al. Imaging features of haematological malignancies of kidneys. Clin Radiol. 2016;71(3):195–202.
   PubMed Web of Science ®Google Scholar
• Okuno SH, Hoyer JD, Ristow K, et al. Primary renal non-Hodgkin’s lymphoma. An unusual extranodal site. Cancer. 1995;75(9):2258–2261.
   PubMed Web of Science ®Google Scholar
• Urban BA, Fishman EK. Renal lymphoma: CT patterns with emphasis on helical CT. Radiogr Rev Publ Radiol Soc N Am Inc. 2000;20(1):197–212.
   Google Scholar
• Törnroth T, Heiro M, Marcussen N, et al. Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis off J Natl Kidney Found. 2003;42(5):960–971.
   PubMed Web of Science ®Google Scholar
• Nicolau C, Sala E, Kumar A, et al. Renal masses detected on FDG PET/CT in patients with lymphoma: imaging features differentiating primary renal cell carcinomas from renal lymphomatous involvement. AJR Am J Roentgenol. 2017;208(4):849–853.
   PubMed Web of Science ®Google Scholar
• Morel P, Dupriez B, Herbrecht R, et al. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d’Etude des Lymphomes de l’Adulte. Br J Cancer. 1994;70(1):154–159.
   PubMed Web of Science ®Google Scholar
• van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178–1184.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol off J Eur Soc Med Oncol ESMO. 2000;11(6):685–690.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol off J Eur Soc Med Oncol ESMO. 2006;18(1):149–157.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Sehn LH, et al. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011; 96(7):1002–1007.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. JCO. 2016;34(26):3150–3156.
   PubMed Web of Science ®Google Scholar
• Xiao JC, Walz-Mattmüller R, Ruck P, et al. Renal involvement in myeloproliferative and lymphoproliferative disorders. A study of autopsy cases. Gen Diagn Pathol. 1997;142(3-4):147–153.
   PubMedGoogle Scholar
• Garcia M, Konoplev S, Morosan C, et al. MALT lymphoma involving the kidney: a report of 10 cases and review of the literature. Am J Clin Pathol. 2007;128(3):464–473.
   PubMed Web of Science ®Google Scholar
• Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–630.
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Shamsuddin AM. The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia. Hum Pathol. 1981;12(5):432–440.
   PubMed Web of Science ®Google Scholar
• Barcos M, Lane W, Gomez GA, et al. An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer. 1987;60(4):827–837.
   PubMed Web of Science ®Google Scholar
• Strati P, Nasr SH, Leung N, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015;100(9):1180–1188.
   PubMed Web of Science ®Google Scholar
• Ong DM, Cummins KD, Pham A, et al. PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. BMJ Case Rep. 2015;2015:bcr2015211159.
   PubMedGoogle Scholar
• Burg G. Systemic involvement in mycosis fungoides. Clin Dermatol. 2015;33(5):563–571.
   PubMed Web of Science ®Google Scholar
• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. JCO. 2017;35(18):2008–2017.
   PubMed Web of Science ®Google Scholar
• Li S-J, Chen H-P, Chen Y-H, et al. Renal involvement in non-Hodgkin lymphoma: proven by renal biopsy. PloS One. 2014;9(4):e95190.
   PubMed Web of Science ®Google Scholar
• Poitou-Verkinder A-L, Francois A, Drieux F, et al. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma: a 25-year multicenter experience. PloS One. 2015;10(3):e0119156.
   PubMed Web of Science ®Google Scholar
• Kunthur A, Wiernik PH, Dutcher JP. Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am J Hematol. 2006;81(4):271–280.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. JCO. 2017;35(31):3529–3537.
   PubMed Web of Science ®Google Scholar
• Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol off J Eur Soc Med Oncol. 2013;24(8):2119–2123.
   PubMed Web of Science ®Google Scholar
• Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma. 2013;54(9):1908–1914.
   PubMed Web of Science ®Google Scholar
• Chihara D, Asano N, Ohmachi K, et al. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol off J Eur Soc Med Oncol. 2015;26(5):966–973.
   PubMed Web of Science ®Google Scholar